Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. Recherche
  • icone plus

  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte

  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités

1 result

  • Active substance : raltitrexed
  • Topics : Diseases and conditions
  • Topics : Nervous system diseases
  • Topics : Screening, prevention
Filter
Topic
  • Economics and public health (1)
  • Plus ...
    • Screening, prevention (1)
  • Diagnostic and therapeutic techniques (1)
  • Plus ...
    • Diagnostic techniques and procedures (1)
    • Plus ...
      • Biology (laboratory tests) (1)
  • Diseases and conditions (1)
  • Plus ...
    • Nervous system diseases (1)
    • Plus ...
      • Nervous system cancers (1)
    • Digestive system diseases (1)
    • Plus ...
      • Digestive system cancers (1)
    • Cancers - miscellaneous (1)
    • Breast diseases (1)
    • Plus ...
      • Breast cancers (1)
Content type
  • Drugs, devices and medical acts (1)
  • Plus ...
    • Health technology assessment (1)
Language
  • Français (1)
Active substance
  • acide folinique (1)
  • carboplatine (1)
  • fluorouracil (1)
  • fluorouracile (1)
  • oxaliplatine (1)
  • raltitrexed (1)
  • thymidine (1)
  • uracile (1)
  • uridine (1)
 More filter Other Filter Icon
Search Export

Drugs, devices and medical acts - 1 result

  • Screening for dihydropyrimidine dehydrogenase deficiency to decrease the risk of severe toxicities related to fluoropyrimidines (5-fluorouracil or capecitabine) - INAHTA Brief

    Health technology assessment - Posted on 29/9/2023
    Download document
    Add to my selection

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
8zaFwBcruL6YPhLJ